Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women

Table 2

Longitudinal analysis: covariates associated with each outcome variable^a assessed from baseline through 36 months (𝑁=224).

Outcome variable	Independent variable	Likelihood ratiob	Parameter estimate	Std. error	t value	Pr(>t)
LDL-C	Androidal fat mass	8.93	0.274	0.092	2.99	0.0029
	Site		16.102	2.649	6.08	≤0.0001
HDL-C	Androidal fat mass	41.13	−0.337	0.052	−6.51	≤0.0001
	Site		−6.819	1.941	−3.51	0.0005
	Time point 12		1.479	1.065	1.39	0.17
	Time point 24		2.106	1.066	1.98	0.049
	Time point 36		3.607	1.066	3.38	0.0008
Triacylglycerol	Androidal fat mass	73.19	0.006	0.001	8.79	≤0.0001
	Site		−0.045	0.019	−2.37	0.019
Glucose	Androidal fat mass	36.13	0.165	0.031	5.28	0.0032
	Site		−2.310	0.894	−2.59	0.010
	Time point 12		2.802	1.015	2.76	0.0059
	Time point 36		3.599	1.015	3.55	0.0004
	FamHx “don’t know”		6.868	2.303	2.98	0.0032
Uric Acid	Androidal fat mass	49.30	0.027	0.004	7.19	≤0.0001
	Site		0.427	0.112	3.81	0.0002

aEach final longitudinal model included obligatory variables: treatment (control versus combined treatment with 80 mg or 120 mg of isoflavones), time point (baseline versus 12, 24, or 36 months), treatment by time point interaction, and site (ISU versus UCD), as well as potential covariates that included androidal fat mass (kg) adjusted for height, time since last menstrual period (TLMP), family history of CVD (Fam Hx) coded as a categorical variable (none versus positive or none versus unknown), and Healthy Eating Index (HEI) score. This table shows only those covariates that were significant (𝑃≤.05) for each outcome variable or had a tendency (𝑃≤.10) to be significant.
bThe likelihood ratio for each model represents the ratio of a model that includes only obligatory variables compared to the final model that includes obligatory variables and covariates. The overall P value for each model was ≤.0001, except the LDL model had a P value =.0028.